SOURCE: Cutting Edge Information

Cutting Edge Information

July 22, 2015 10:00 ET

44% of Surveyed Companies Use Health Outcomes Liaisons to Deliver Comparative Effectiveness Data to Payers, According to Cutting Edge Information

RESEARCH TRIANGLE PARK, NC--(Marketwired - July 22, 2015) - New research from pharmaceutical intelligence firm Cutting Edge Information shows that health outcomes liaisons (HOLs) are playing a large role in sharing comparative effectiveness research (CER) with payers. Increasing price-sensitivity in the United States and the Europe is driving groups to find more effective ways of communicating product value to key external stakeholders.

Comparative effectiveness teams at pharmaceutical companies are looking to work closely with HOLs to deliver CER to payers. While managed markets account managers and medical science liaisons still represent the majority of companies to payers, the HOL role is growing and is expected to continue growing.

"HOLs have a specialized skillset that allows them to deliver cohesive comparative effectiveness messages within the larger health economics value story," said Jacob Presson, senior analyst at Cutting Edge Information. "HOLs -- because of their dual financial and clinical background -- are considered more effective communicators of complex comparative effectiveness data."

According to Cutting Edge Information's newest report, "Comparative Effectiveness Research: Value Stories that Engage Patients, Physicians and Payers," the usage of HOLs in comparative effectiveness discussions is now considered a best practice among many top companies and is expected to continue growing. Among smaller companies where the number of HOLs is limited or even nonexistent, companies will train managed markets account managers.

"Comparative Effectiveness Research: Value Stories that Engage Patients, Physicians and Payers," available at, provides metrics on the cost and duration of comparative effectiveness studies, as well as how to best deliver this data to external stakeholders. The report examines the changing priorities with regards to conducting comparative effectiveness research in the US. Highlights include:

  • Benchmarking data showing total comparative effectiveness spending and CER spending per product from 2013 to 2015
  • Top executives' strategic recommendations for delivering CER data to payers -- and using health outcomes liaisons to supplement managed markets account managers' efforts
  • Data showing the amount of time spent discussing CER with payers

For more information about "Comparative Effectiveness Research: Value Stories that Engage Patients, Physicians and Payers," and other health economics related topics, please download the report summary at

Image Available:

Contact Information